Are pharma-doc links necessary or questionable?

Questionable links between doctors and the pharma industry reached their apogee in the U.S. at the start of the millennium, when fierce competition among companies at a time of slowing innovation resulted in the creation of a slew of “me too” drugs, often with little advantage over existing treatment, the Financial Times reports. Report

Suggested Articles

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.

The FDA knocked India's Panacea Biotec for failing to adequately identify isolated microbes in its aseptic manufacturing facility.

Teva repeatedly raised prices on Copaxone and used aggressive strategies to grow its market and fend off competition, a congressional report finds.